The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer
Official Title: A Phase 2, Randomized, Proof-of-Concept Study of Nab-Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer
Study ID: NCT02570711
Brief Summary: To evaluate the safety and efficacy of ACP-196 and nab paclitaxel/gemcitabine in subjects with previously untreated metastatic pancreatic cancer using standard response criteria
Detailed Description: A Phase 2, multicenter, open-label, randomized clinical trial. The study was to evaluate the efficacy and safety of ACP-196 plus nab-paclitaxel/gemcitabine compared with nab-paclitaxel/gemcitabine in subjects who have previously untreated metastatic pancreatic cancer.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Ventura Clinical Trials, Ventura, California, United States
Florida Cancer Specialists, Fort Myers, Florida, United States
Duke University Medical Center, Durham, North Carolina, United States
Oncology Hematology Care, Cincinnati, Ohio, United States
Cleveland Clinic, Cleveland, Ohio, United States
Tennessee Oncology, Chattanooga, Tennessee, United States
Tennessee Oncology, Nashville, Tennessee, United States
The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
International Cancer Center, Houston, Texas, United States
Name: Acerta Clinical Trial
Affiliation: 1-888-292-9613; acertamc@dlss.com
Role: STUDY_DIRECTOR